New Developments in Secondary Stroke Prevention: Impact of the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) on Clinical Management

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Secondary stroke prevention is an important goal of poststroke patient treatment. Various pharmacologic approaches have been advocated, but the relative efficacy and safety of these regimens has remained the subject of much debate. Recently released data from the European/Australasian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) indicated that combination therapy with aspirin and extended-release dipyridamole was more effective than aspirin monotherapy, and probably more effective than anticoagulants, for the prevention of cerebrovascular events after a stroke or transient ischemic attack. When viewed in light of results of earlier trials, these findings confirmed that combination aspirin plus extended-release dipyridamole therapy improved outcomes in these patients and is a recommended option for poststroke patient treatment.

Original languageEnglish (US)
Pages (from-to)263-267
Number of pages5
JournalJournal of Stroke and Cerebrovascular Diseases
Volume16
Issue number6
DOIs
StatePublished - Nov 1 2007

    Fingerprint

Keywords

  • Antiplatelets
  • aspirin
  • dipyridamole
  • secondary stroke prevention
  • stroke

ASJC Scopus subject areas

  • Surgery
  • Rehabilitation
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this